Top Markets
#1 Black Phoenix Black Phoenix +342.75%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +61.75%
#4 Gold Park Gold Park +55.03%
#5 Acurast Acurast +36.76%
#6 BasedHype BasedHype +29.90%
#7 Cryptopia Cryptopia +22.04%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.03%
#9 Avantis Avantis +18.81%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +14.74%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Destiny Pharma plc Destiny Pharma plc

Destiny Pharma plc

DEST
Classement en actions #41142
Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in... Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.
Prix de l'action
$0.04082105
Dernière synchronisation: 2024-08-12
Capitalisation boursière
$39.09K
Changement (1 jour)
-19.83%
Changement (1 an)
0.00%
Pays
GB
Échange Destiny Pharma plc (DEST)

Catégorie

Healthcare
Ratio P/S pour Destiny Pharma plc (DEST)
Ratio P/S au August 2026 TTM : 3.46
Selon les derniers rapports financiers et le cours de l'action de Destiny Pharma plc, le ratio cours/ventes actuel (TTM) est 3.46. À la fin de 2022, le ratio P/S était de 243.09.
Historique du ratio P/S pour Destiny Pharma plc de 2013 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 3.46 -95.47%
2023 76.33 -68.60%
2022 243.09 -47.78%
2021 465.54 -81.29%
2020 2.49K 3,941.09%
2019 61.58 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 185.98%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 198.20%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 44.11%
BE